Skip to NavigationSkip to content

FDA offer priority review for Genentech's Rituxan in children

Published on 13/06/19 at 09:28am

The FDA will offer priority review to Genentech’s supplemental biologics-license application (sBLA) application for Rituxan for children with two rare blood vessel disorders.

The Roche subsidiary’s sBLA covers Rituxan’s use in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older.

The FDA offers priority review to drugs that have the might provide significant benefits in the treatments of serious diseases.

Rituxan has in the past been approved for immunological diseases and various forms of cancer. However if approved, the sBLA application would mark the first paediatric indication for the drug.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches